RT Book, Section
A1 Hall, Michael E.
A1 Hall, John E.
A1 Whelton,  Paul K.
A2 Fuster, Valentin
A2 Narula, Jagat
A2 Vaishnava, Prashant
A2 Leon, Martin B.
A2 Callans, David J.
A2 Rumsfeld, John S.
A2 Poppas, Athena
SR Print(0)
ID 1205976292
T1 Epidemiology, Pathophysiology, and Treatment of Hypertension
T2 Fuster and Hurst's The Heart, 15e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264257560
LK accesscardiology.mhmedical.com/content.aspx?aid=1205976292
RD 2024/04/19
AB Content  UpdateSustained  Blood  Pressure  Reduction  With  the  RNA  Interference  Therapeutic  Zilebesiran:  Primary  Results  From  KARDIA-1,  a  Phase  2  Study  in  Patients  With  HypertensionThe  KARDIA-1  trial  was  a  randomized,  blinded,  phase  2  study  of  zilebesiran,  an  investigational  long-acting  RNA  interference  agent  that  inhibits  hepatic  angiotensinogen  synthesis  by  reducing  liver  angiotensinogen  mRNA  levels.  Read  More